Effectiveness and safety of interferon α-2a combined with phototherapy for patients with early-stage mycosis fungoides - a single-arm prospective study in 13 patients

Article

Author: Yang, Lu ; Song, Hongbin ; Lu, Lu ; Wang, Tao ; Feng, Jindi ; Zhang, Shiyu ; Hu, Zhonghui ; Liu, Yuehua

Background: Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma.Objectives: This study was conducted to evaluate efficacy and safety of interferon (IFN) α-2a combined with phototherapy for early-stage MF.Methods: Thirteen patients with early-stage MF received subcutaneous injections of IFN α-2a at 3 million IU combined with phototherapy three times per week for 6 months. Treatment efficacy was measured by changes in body surface area (BSA) score and modified severity-weighted assessment tool (mSWAT) score at 1, 3, and 6 months after treatment. Histopathologic examinations of skin lesions were performed before and after treatment.Results: After 3 months of treatment, all 13 patients achieved a partial response, and BSA and mSWAT scores were significantly lower than those at baseline (p < 0.001). After 6 months, BSA and mSWAT scores were significantly lower than those at baseline (p < 0.001) and after 3 months (p < 0.05). Eleven patients achieved complete remission and two patients achieved a partial response (overall response rate, 100%). Histopathologic examination showed a significant decrease in the number of atypical lymphocytes in both epidermis and dermis. No severe adverse effects occurred.Conclusion: IFN α-2a in combination with phototherapy may be an effective and safe alternative modality for early-stage MF.

14 Aug 2024·British Journal of Dermatology

Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study

Article

Author: Bagot, Martine ; Lora-Pablos, David ; Guenova, Emmanuella ; Hodak, Emmilia ; Beylot-Barry, Marie ; Ortiz, Pablo ; Quaglino, Pietro ; Amitay-Laish, Iris ; Mitsunaga, Keila ; Cury-Martins, Jade ; Porkert, Stefanie ; Ram-Wolff, Caroline ; Nicolay, Jan ; Jonak, Constanze ; von Gugelberg, Christina ; Applewaite, Rona ; Sanches, José Antonio ; Papadavid, Evangelia ; Scarisbrick, Julia

AbstractBackgroundMycosis fungoides (MF) and Sézary syndrome (SS) are chronic malignant diseases that typically necessitate diverse strategies to achieve remission. Systemic interferon (IFN)-α (subtypes 2a and 2b) has been used to treat MF/SS since 1984; however, its production was recently stopped. The recombinant pegylated (PEG) form of IFN-α-2a remains the only alternative IFN treatment, although it has not been approved for use in MF/SS.ObjectivesTo assess the effectiveness and safety of PEG-IFN-α-2a in monotherapy and in combination with other treatments using time to next treatment (TTNT) as a measure of clinical therapeutic benefit in a real-world setting.MethodsWe conducted an international, multicentre retrospective study of patients with MF and SS (of any stage) treated with PEG-IFN-α-2a from July 2012 to February 2022. Patients were included across 11 centres in 10 countries. The primary endpoints were to determine the TTNT of PEG-IFN-α-2a and adverse events (AEs) in MF/SS.ResultsIn total, 105 patients were included [mean (SD) age 61 (13.1) years]; 42 (40.0%) had stage IA–IIA and 63 (60.0%) had stage IIB–IVB disease. PEG-IFN-α-2a was combined with other therapies in 67 (63.8%) patients, most commonly with extracorporeal photopheresis (36%) and bexarotene (22%). Patients with stage I–IIA disease achieved an overall response rate (ORR) of 57%; the ORR in those with stage IIB–IVB disease was 51%. Combination treatment resulted in a median TTNT of 10.4 months (range 0.6–50.7) vs. 7.0 months (range 0.7–52.4) for those who received monotherapy (P < 0.01). Overall, the mean (SD) TTNT was 9.2 (10.6) months and the ORR was 53.3% (n = 56). A complete response was seen in 13% of patients and a partial response in 40%. AEs were described in 68.6% (n = 72) of patients. Flu-like symptoms (n = 28; 26.7%), lymphopenia (n = 24; 22.9%) and elevated liver function (n = 10; 9.5%) were the most frequently reported. Grade 3–4 AEs were reported in 23 (21.9%) patients, mostly related to myelosuppression.ConclusionsPEG-IFN-α-2a for MF/SS resulted in an ORR of 53.3% and a mean (SD) TTNT of 9.2 (10.6) months. Combination regimens were superior to monotherapy and doses of 180 µg PEG-IFN-α-2a weekly were related to a higher ORR.

01 Apr 2022·Dermatologic Therapy

Complete remission with bexarotene gel in unilesional folliculotropic mycosis fungoides located on the scalp

Letter

Author: Kalay Yildizhan, Incilay ; Sanli, Hatice ; Demirci Saadet, Elif ; Okcu Heper, Aylin

A review.Bexarotene 1% gel is an effective and generally well-tolerated treatment option for early stage cutaneous T cell lymphoma (CTCL) patients who are resistant or intolerant to other topical therapies, with less than 15% body surface area involvement.Bexarotene 1% gel was initiated as monotherapy 2 mo after discontinuation of IFN-a-2a and patient began to use bexarotene gel once daily initially, and the dose was increased weekly to twice a day and three times a day and four times a day, resp.Bexarotene is a retinoid, selectively binds retinoid X receptors(RXRs), and activated RXRs can function as transcription factors that regulate the expression of genes controlling cellular differentiation, proliferation, and apoptosis.The present case is the first reported FMF patient refractory to IFN-a-2a therapy and treated with topical bexarotene gel successfully.Bexarotene gel may be considered as a good option in localized early-stage FMF even refractory to systemic treatment.

100 Deals associated with Interferon alpha-2a biosimilar(Rhein-Minapharm)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB04	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hepatitis C	EG	Rhein-Minapharm	01 Jan 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis